跳至主要内容
临床试验/EUCTR2012-005066-36-NL
EUCTR2012-005066-36-NL进行中(未招募)不适用

Effect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentration - GH and cardiovascular risk factors

VU University Medical Center0 个研究点开始时间: 2013年1月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Ongoing surveillance at our centre (VUmc, Amsterdam)
  • - GH treated (at least one year)
  • - Men and women with an age between 20 and 65 years, both childhood as adult onset GHD
  • - Stable substitution therapies for other pituitary hormone deficiencies
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 32
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Subjects with a craniopharyngioma as cause of their GHD or pituitary deficiencies
  • - Contraindications for the use of Growth Hormone treatment
  • - (Receiving treatment for) malignant disease (in the past)
  • - Cardiovascular event less than one year prior to inclusion
  • - Participation in other studies
  • - Subjects, who in the opinion of the investigator, are unsuitable in any other way to participate in this study

研究者

发起方
VU University Medical Center

相似试验